A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Status:
RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This is a single center, single arm, open-label, dose-escalation clinical study to observe the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics of ESO-T01 injection for treating patients with relapsed/refractory multiple myeloma.